We support individuals with ADHD and other treatment-resistant conditions, including chronic pain, anxiety, and trauma-related presentations, where standard treatment approaches have been ineffective, contraindicated, or not tolerated. Where clinically appropriate, and following a comprehensive clinical assessment, cannabis-based medicinal products (CBMPs) may be considered in line with UK legislation and current regulatory guidance.
All assessments are undertaken by appropriately qualified clinicians, including GMC-registered consultants with experience in managing complex and co-morbid presentations. Treatment options are discussed collaboratively with patients and are considered only after a full consultation and multidisciplinary review.
Access to CBMPs is not guaranteed and is determined strictly on a case-by-case basis, in accordance with UK law, professional standards, and patient safety requirements.
For more information, click here to go to our full website
Click here for our full price list
(ISC-CARE provides clinical assessments only. Cannabis-based medicinal products are considered only where clinically appropriate following specialist assessment and are not guaranteed.)
